Core Insights - Coherus Oncology is transitioning into an innovative oncology company focused on overcoming immune resistance in cancer, with a strong emphasis on its commercial PD-1 therapy LOQTORZI and new pipeline assets acquired from Surface Oncology [5][22]. Group 1: LOQTORZI Overview - LOQTORZI is described as a next-generation PD-1 therapy with high-affinity binding, effective in low PD-L1 cancers, and is currently labeled for low PD-L1 esophageal cancer in the EU [1]. - Sales of LOQTORZI increased significantly from $19.1 million in 2024 to $40.8 million in 2025, with expectations of reaching $15–16 million per quarter in 2026 and targeting a 70% market share by 2028, equating to approximately $175 million annualized [7][10]. - The company is pursuing a $33 billion opportunity based on ongoing trials in the U.S. [2]. Group 2: Financial Developments - Coherus completed the sale of UDENYCA to Intas for an upfront payment of $483 million, with additional payments expected, which will support the company's financial stability [3]. - The company has paid down nearly $480 million in debt and retained $250 million on its balance sheet to fund development efforts [4][7]. Group 3: Pipeline Progress - The pipeline includes tagmokitug, a CCR8 Treg depleter, and casdozokitug, an IL-27 blocker, with promising clinical outcomes reported, including a 38% overall response rate in first-line hepatocellular carcinoma [6][17]. - Tagmokitug is being studied in various cancers, including head and neck and gastrointestinal cancers, and is expected to enter prostate cancer studies in collaboration with Johnson & Johnson [12][15]. - Coherus is also exploring additional collaborations for tagmokitug and casdozokitug, aiming for ex-U.S. licensing to manage development costs [21].

Core Insights - Coherus Oncology reported significant growth in LOQTORZI net revenue, which more than doubled to $40.8 million in 2025 from $19.1 million in 2024, indicating strong market demand and successful sales strategies [1][2] - The company successfully reduced its secured and convertible debt by 90%, decreasing from $480 million to $38.8 million over the period of 2024-2025, enhancing its financial stability [1][2] - As of December 31, 2025, Coherus had $172.1 million in cash, cash equivalents, and marketable securities, reflecting a solid liquidity position [1][17] Financial Performance - For Q4 2025, net revenue from continuing operations was $12.7 million, up from $7.7 million in Q4 2024, driven by increased demand for LOQTORZI [5][9] - The cost of goods sold (COGS) for Q4 2025 was $4.0 million, compared to $2.8 million in Q4 2024, primarily due to volume growth of LOQTORZI [10] - Research and development (R&D) expenses rose to $31.0 million in Q4 2025 from $20.8 million in Q4 2024, reflecting increased investment in pipeline candidates [11] Pipeline Development - Coherus is advancing its innovative oncology pipeline, including casdozokitug, which is in a Phase 2 study for hepatocellular carcinoma, and tagmokitug, a highly selective CCR8 targeting antibody [2][21] - Tagmokitug has shown promising results in preclinical studies, demonstrating high selectivity and significant efficacy in depleting CCR8+ tumor regulatory T cells [4][6] - The company plans to initiate combination studies with tagmokitug and LOQTORZI, as well as with Johnson & Johnson's T-cell engager pasritamig in metastatic castration-resistant prostate cancer [2][13] Market Position - LOQTORZI remains the only FDA-approved treatment in the U.S. for recurrent, locally advanced, or metastatic nasopharyngeal carcinoma, representing a $250 million addressable market [5] - The company is strategically positioned with growing revenues from LOQTORZI and potential deal opportunities across its portfolio, indicating a robust market presence [2][20]

Core Insights - Coherus is launching LOQTORZI for nasopharyngeal carcinoma (NPC), addressing an unmet medical need with an estimated 2,000 patients annually who previously relied on chemotherapy or off-label immuno-oncology treatments [1] - The company has undergone a significant transformation, enhancing its team, board, and investor base, and has recently completed a financing round, resulting in a strong balance sheet with cash reserves [2] - Coherus has reduced its debt by approximately 90%, from about $480 million to $3.7 million, and added $250 million to its balance sheet, which supports its oncology pipeline development [3][7] Commercial Launch and Financial Performance - LOQTORZI's commercialization is accelerating, generating about $19 million in sales in 2024, with sales doubling in 2025, and the company expects to reach a self-funding status at approximately $15-16 million per quarter by 2026 [6][8] - Management targets a run rate of roughly $175 million per year by 2028, representing about 70% penetration of a $250 million market opportunity [17] - LOQTORZI has shown a significant overall survival benefit of 65 months compared to 34 months with chemotherapy alone, and it is listed as the only "preferred" option in the NCCN guidelines for NPC [9] Pipeline Developments - Coherus is advancing its pipeline with tagmokitug (anti-CCR8) showing selective tumor Treg depletion of 52-97% without dose-limiting toxicities, and casdozokitug (anti-IL-27) demonstrating liver/lung-specific activity [5][16] - A randomized phase II readout for casdozokitug is expected in mid-2026, with ongoing studies showing improved response rates in liver cancer when combined with standard therapies [19][20] - The company is pursuing partnerships to share costs in pivotal trials for its pipeline assets, including collaborations with Johnson & Johnson [14][15] Strategic Focus - Coherus is focused on three main priorities: enhancing the commercial launch of LOQTORZI, advancing its pipeline assets, and implementing a financial strategy to reduce development costs while maximizing shareholder value [21]

Coherus Oncology FY Conference Summary Company Overview - **Company**: Coherus Oncology (NasdaqGM:CHRS) - **Date of Conference**: March 04, 2026 - **Focus**: Transformation into an innovative oncology company, with significant debt reduction and product development initiatives Key Metrics and Financials - **Debt Reduction**: Reduced indebtedness by 90%, from approximately $480 million to $3.7 million in senior secured debt [2][6] - **Cash Position**: Strong balance sheet with $172 million at the end of Q4, further improved with recent financing [9] - **Sales Growth**: Sales of LOQTORZI increased from $19 million in 2024 to approximately $38 million in 2025, with expectations for continued growth in 2026 [5][10] Product Development and Pipeline LOQTORZI - **Indication**: Nasopharyngeal carcinoma (NPC) with a significant unmet need; launched in 2024 [7] - **Market Opportunity**: Estimated market size of $250 million, with a target of achieving $175 million in annual sales by 2028 [11] - **Sales Strategy**: Enhanced commercial team and sophisticated data acquisition tools to identify and reach patients [8][9] - **Clinical Data**: Demonstrated overall survival benefit of 65 months with LOQTORZI compared to 34 months with chemotherapy alone [4] Tagmokitug (Anti-CCR8 Antibody) - **Mechanism**: Targets T-regulatory cells (Tregs) selectively, showing 52%-97% depletion in tumors without affecting CD4s and CD8s [15][16] - **Tumor Types**: High potential across various solid tumors including head and neck, gastrointestinal, and breast cancers [17] - **Clinical Development**: Ongoing studies to optimize dosing and understand the best contexts for treatment [18][19] - **Partnerships**: Interest from larger companies for collaborations, particularly in combination therapies [23][24] Casdozokitug (Anti-IL-27) - **Mechanism**: Inhibits IL-27 to activate T cells and NK cells, showing promising results in liver and lung cancers [36][39] - **Clinical Data**: Achieved a 17% complete response rate in liver cancer, significantly higher than the previous highest of 8% [41] - **Ongoing Studies**: Randomized phase 2 study with initial readout expected mid-year 2026 [43] Strategic Insights - **Transformation Strategy**: Focus on product, clinical, and financial strategies to enhance investor value [52] - **Market Positioning**: Coherus aims to leverage its unique product offerings and partnerships to address significant gaps in oncology treatment [24][25] - **Future Outlook**: Anticipation of strong data readouts and continued growth in sales and clinical advancements [53] Additional Considerations - **Collaborative Opportunities**: Open to various licensing and partnership arrangements to reduce clinical trial costs and enhance development capabilities [25] - **Biomarker Strategy**: Potential to develop a biomarker strategy based on CCRA presence in tumors to enrich patient populations [32] This summary encapsulates the key points discussed during the Coherus Oncology FY Conference, highlighting the company's strategic direction, product pipeline, and financial health.

Coherus Oncology Conference Call Summary Company Overview - **Company**: Coherus Oncology - **Ticker**: NasdaqGM:CHRS - **Industry**: Oncology Key Points Company Value Proposition - Coherus Oncology's value proposition is summarized as "drugs, data, and deals" [2][28] - The company focuses on innovative oncology treatments, particularly in the PD-1 space with LOQTORZI and emerging therapies like CHS-114 and casdozokitug [2][3] Product Pipeline - **LOQTORZI**: A foundational PD-1 product approved for nasopharyngeal cancer, expected to generate revenue and expand its label with ongoing studies [4][6] - **CHS-114**: A highly selective Treg depleter, recognized as an important therapeutic approach, with studies in colorectal and gastric cancers [3][4][19] - **Casdozokitug**: An anti-IL-27 therapy being developed for liver and lung cancers, showing promising early data [3][21] Market Potential - The combined pipeline addresses a market opportunity of approximately **$30 billion** in the U.S. across multiple cancer indications [6] - LOQTORZI is projected to reach a revenue range of **$150-$200 million** by mid-2028, with a growth rate of **10%-15%** in recent quarters [9][10] Clinical Studies and Data - Ongoing studies for CHS-114 in colorectal and gastric cancers, with data expected in **2026** [5][19] - Casdozokitug has shown a **60%** tumor shrinkage rate and a **38%** overall response rate in initial studies, significantly outperforming standard care [24] Strategic Partnerships and Licensing - Coherus has a strong track record of divesting biosimilar assets, raising nearly **$800 million** and paying off **$480 million** in debt [25][26] - The company is focused on collaborations to enhance patient survival through combination therapies, leveraging its PD-1 and other products with partners [26][27] Scientific Innovations - LOQTORZI's mechanism involves high-affinity binding at the FG loop, leading to significant T cell signaling advantages [8] - CHS-114 targets CCR8 on Treg cells in the tumor microenvironment, aiming to enhance immune response against tumors [11][14] Future Outlook - Coherus is optimistic about the outcomes of ongoing studies and the potential for expanding its pipeline into additional cancer types [20][28] - The company is actively seeking to validate its pipeline through partnerships and collaborations, which will also help offset clinical trial costs [27][28] Additional Insights - The company emphasizes the importance of Treg depletion in treating "cold" tumors, which represent **70%** of certain cancer types [12][19] - The strategic acquisition of Surface Oncology for **$65 million** has positioned Coherus for innovative oncology advancements [26] This summary encapsulates the key insights from the Coherus Oncology conference call, highlighting the company's strategic direction, product pipeline, market potential, and scientific innovations.

Coherus Oncology Conference Call Summary Company Overview - Coherus Oncology transitioned to being solely an innovative oncology company after divesting its biosimilar business in Q2 2025, marking Q3 2025 as its first quarter focused exclusively on oncology [6][13] - The company reported $198 million in cash on its balance sheet at the end of Q3 2025, indicating strong financial management [13] Pipeline Programs Toripalimab (LOQTORZI) - Toripalimab is a next-generation PD-1 inhibitor with unique binding sites, demonstrating activity in low PD-L1 states [7] - Approved for front-line and second-line nasopharyngeal carcinoma in 2023, generating $11 million in revenue in Q3 2025, a 12% increase from Q2 2025 [17][19] - The drug has shown a strong hazard ratio, extending survival from 22 months to over 48 months in nasopharyngeal cancer patients [18] - The company aims for 10-15% revenue growth, targeting $150-$200 million by 2028 [20] - Adoption is strong among academic physicians, but community physicians require more education about the drug [21][22] - Combination strategies with other therapeutics are being explored to enhance treatment efficacy [15][16] CHS-114 (CCR8 Targeting) - CHS-114 is a highly selective molecule targeting CCR8, which plays a significant role in Treg cells within the tumor microenvironment [26][28] - The drug is designed to deplete Tregs, potentially allowing CD8 positive T cells to infiltrate tumors, which is crucial for effective immunotherapy [30][34] - The clinical program is strategically designed to evaluate efficacy across various cancers, including head and neck, gastric, and colorectal cancers [32][35] - The company is optimistic about the potential for CHS-114 to show significant activity in underserved tumor types [32] Casdozokitug - Casdozokitug is an anti-IL-27 molecule showing promising efficacy in liver cancer, with a focus on improving overall response rates and progression-free survival [50][51] - The company anticipates data from ongoing studies in the first half of 2026, which will inform the design of future phase two and three trials [47][48] Strategic Partnerships and Deals - Coherus has global rights to its products, allowing for flexibility in forming partnerships, particularly in Asian markets for liver cancer treatments [12][53] - The company is open to collaborations with other biotech firms to enhance the development of its products [40][41] - Upcoming deals are expected to validate the value of its assets and provide upfront funding to offset clinical costs [53][54] Key Catalysts and Future Outlook - The company is focused on delivering data in 2026 that will support the advancement of its pipeline products [34][46] - Coherus is positioned to leverage its scientific leadership and partnerships to enhance patient outcomes and drive growth [45][46] - The next 12-18 months are expected to be pivotal for the company, with significant updates anticipated from ongoing studies and potential partnerships [52][55]

Core Insights - Coherus Oncology has expanded its clinical program for CHS-114, a selective Treg depleter, to include colorectal cancer, addressing a significant unmet medical need [1][2] - The company reported a net revenue of $11.2 million for LOQTORZI in Q3 2025, marking a 12% increase from Q2 2025 and a 92% increase from Q3 2024 [5][8] - As of September 30, 2025, Coherus had cash, cash equivalents, and marketable securities totaling $191.7 million [16] Recent Business Highlights - LOQTORZI is the only FDA-approved treatment for recurrent, locally advanced, or metastatic nasopharyngeal carcinoma in the U.S. [5] - The growth in LOQTORZI's revenue is attributed to increased patient demand and awareness of updated NCCN guidelines [5] - The company is focusing on expanding its oncology pipeline, including combining LOQTORZI with internal candidates like CHS-114 and casdozokitug [4][19] Financial Performance - For Q3 2025, net revenue from continuing operations was $11.6 million, compared to $6.1 million in Q3 2024, and $29.4 million for the nine months ended September 30, 2025, compared to $18.7 million in the same period of 2024 [8][14] - Research and development expenses increased to $27.3 million in Q3 2025 from $22.1 million in Q3 2024, driven by the development of casdozokitug and CHS-114 [10] - The net loss from continuing operations for Q3 2025 was $44.5 million, a slight improvement from a net loss of $47.6 million in Q3 2024 [14][15] Pipeline Developments - CHS-114 is currently in Phase 1b/2a studies targeting various cancers, including head and neck squamous cell carcinoma and colorectal cancer [21] - Casdozokitug is being evaluated in a Phase 2 study for first-line hepatocellular carcinoma, showing promising monotherapy activity in treatment-refractory non-small cell lung cancer [7][21] - Initial data readouts for ongoing studies are expected throughout 2026, indicating a robust pipeline for the company [2][11]

Core Insights - Coherus Oncology has appointed Arvind Sood as Chief Strategy and Corporate Affairs Officer to enhance its strategic functions and investor relations [1][2] - The company is focused on advancing its innovative cancer therapeutics, particularly LOQTORZI® and its pipeline candidates, which target various cancers [2][3] - Coherus holds global rights to key products, CHS-114 and casdozokitug, which presents potential business development opportunities [2][4] Company Overview - Coherus Oncology is a commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI®, and a pipeline that includes mid-stage clinical candidates targeting multiple cancers [3] - The company's strategy includes growing LOQTORZI sales in nasopharyngeal carcinoma and developing new indications in combination with pipeline candidates [3] Pipeline Development - Coherus' pipeline features multiple antibody immunotherapy candidates aimed at enhancing immune responses against cancer [4] - CHS-114 is currently in Phase 1b/2a studies for advanced solid tumors, while casdozokitug is being evaluated in a Phase 2 study for hepatocellular carcinoma [4]

Coherus BioSciences Conference Call Summary Company Overview - **Company**: Coherus BioSciences (NasdaqGM:CHRS) - **Focus**: Enhancing the lives of cancer patients and improving survival rates through innovative therapies [5][6] Pipeline and Strategy - **Key Products**: - **LOQTORZI**: Next-generation PD-1 inhibitor - **CHS-114**: Anti-CCR8 antibody T-reg depletor - **Casdozokitug**: Anti-IL-27 antibody - **Development Programs**: - Data expected around mid-2026 for CHS-114 in various cancers including head and neck, gastric, esophageal, and colorectal [6][12] - Active in liver cancer with casdozokitug, showing promising results [6][12] - **Partnerships**: Seeking ex-US partners for pipeline validation and monetary support [6][12] Market Dynamics - **LOQTORZI**: - Approved for frontline and second-line nasopharyngeal carcinoma - Generated approximately $10 million in revenue last quarter, with expectations of substantial market growth [11][12] - Anticipated peak sales between $150 million and $200 million by mid-2028, with a growth rate of 10% to 15% per quarter [12] - **Market Size**: The nasopharyngeal market is estimated at $250 million [12] Competitive Advantages - **LOQTORZI**: - Higher binding affinity (>10x) compared to other PD-1 inhibitors, with unique epitope binding [9][10] - Approved irrespective of PD-L1 status, unlike competitors [9][10] - **CHS-114**: - Selective targeting of CCR8, a key marker in regulatory T cells, with a mechanism that enhances immune response [19][20] - Potential to be a best-in-class asset in immuno-oncology [22][30] Clinical Data and Expectations - **CHS-114**: - Ongoing studies in head and neck cancer, gastric cancer, and esophageal squamous cell carcinoma [25][26] - Early data shows promise with partial responses in late-line patients [24] - **Casdozokitug**: - Demonstrated a 38% overall response rate and a 17% complete response rate in combination with atezolizumab and bevacizumab for hepatocellular carcinoma [39] - Ongoing study with LOQTORZI, aiming to further characterize efficacy and safety [40] Future Outlook - **Data Readouts**: Anticipated results for various studies in mid-2026, with a focus on combination therapies and their contributions to overall efficacy [32][40] - **Strategic Positioning**: Coherus aims to leverage its unique product offerings and partnerships to drive growth and improve patient outcomes [45] Conclusion - Coherus BioSciences is positioned uniquely in the oncology space with a strong pipeline and strategic focus on combination therapies, aiming to deliver significant advancements in cancer treatment and patient survival [45]

Core Insights - Coherus Oncology reported a net revenue of $10.0 million for LOQTORZI, marking a 36% increase from Q1 2025, driven by higher patient demand and inventory restocking [1][6][11] - The company has a cash position of $238 million as of Q2 2025, providing a runway through 2026 for ongoing clinical programs [1][22] - Upcoming data readouts for CHS-114 and casdozokitug are expected in the first half of 2026, indicating progress in the oncology pipeline [1][2][7] Financial Performance - LOQTORZI net revenue increased from $7.3 million in Q1 2025 to $10.0 million in Q2 2025, compared to $3.8 million in Q2 2024 [6][11] - Total net revenue from continuing operations was approximately $10.3 million for Q2 2025, consistent with Q2 2024 [11] - The net loss from continuing operations for Q2 2025 was $44.9 million, a reduction from a net loss of $54.9 million in Q2 2024 [16] Pipeline Development - CHS-114, a cytolytic CCR8 antibody, is in Phase 1b studies, with initial data readouts expected in 1H 2026 [2][7] - Casdozokitug, an IL-27 antagonist, is being evaluated in multiple studies, with a focus on solid tumors [5][25] - The combination of LOQTORZI with internal pipeline candidates is aimed at expanding treatment indications [4][24] Recent Business Highlights - The divestiture of UDENYCA was completed in April 2025, generating $483.4 million in cash, which has been used to pay off significant financial obligations [9][10] - The company is focusing on maximizing LOQTORZI's potential in nasopharyngeal carcinoma, supported by a recent revision in NCCN guidelines granting it preferred status [6][24] Cash Position and Financial Obligations - As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $237.6 million, up from $126.0 million at the end of 2024 [22][33] - The company has settled a majority of UDENYCA-related obligations, which are expected to be resolved in a front-loaded manner over the remainder of 2025 and into 2026 [22]